Identification and targeting of selective vulnerability rendered by tamoxifen resistance

BACKGROUND: The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main hurdle...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res
Hlavní autoři: Singh, Madhurendra, Zhou, Xiaolei, Chen, Xinsong, Santos, Gema Sanz, Peuget, Sylvain, Cheng, Qing, Rihani, Ali, Arnér, Elias S. J., Hartman, Johan, Selivanova, Galina
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7388523/
https://ncbi.nlm.nih.gov/pubmed/32727562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01315-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky